Myogenica was formed in 2022 as a spin out of the University of Minnesota to develop MyoPAXon, an induced pluripotent stem cell (iPSC) platform for muscle regeneration. MyoPAXon has been shown to be effective in regenerating muscle and dramatically improving function in a range of muscular dystrophy models, including Duchenne muscular dystrophy, limb girdle muscular dystrophy and Facioscapulohumeral muscular dystrophy (FSHD). Myogenica’s co-founders are a combination of experts in muscle regeneration, stem cell biology and cell and gene therapy development.